When do biologic drug patents expire and when will biosimilars launch?

US Patent 6,558,674: Claims and Patent Landscape Analysis

United States Patent (US) 6,558,674 is a granted patent with claims tied to a defined subject matter set out in its independent claims, and it sits in a US family/patent landscape shaped by (i) earlier disclosures that narrow novelty, (ii) later improvement filings that target specific implementation choices, and (iii) claim-interpretation outcomes that typically turn on construction of a small number of functional and structural limitations.

This analysis breaks the patent down into (1) claim architecture, (2) claim strength drivers and likely validity/obviousness pressure points, (3) enforceability risks created by claim breadth and antecedent basis, and (4) the surrounding US landscape in terms of citation density and design-around pathways.

Compliance note: A complete and accurate claim-by-claim analysis requires the exact claim text, prosecution history, and the patent’s listed references/citations. Without those, any “comprehensive and critical analysis” would be incomplete by construction.

What does US 6,558,674 claim, and how are the claims structured?

A claim analysis must start from the independent claim(s) and then map each dependent claim to:

a specific additional limitation (structural, compositional, procedural, or functional),
whether that limitation is a design “hook” for infringement,
and whether the same hook appears in closer prior art.

For US 6,558,674, that mapping cannot be completed accurately without the precise wording of:

claim 1 (and any other independent claims),
dependent claim set and numbering,
claim dependencies (what each dependent claim adds),
and the claim construction-relevant terms.

Critical landscape implication: In enforcement and freedom-to-operate work, the risk is usually not “the whole invention is invalid,” but that key claim terms are read broadly in some disputes and narrowly in others. That only becomes actionable once the actual terms are known.

Which claim elements are the likely novelty and non-obviousness pressure points?

In practice, novelty and obviousness collapse around a small number of claim elements, typically:

a specific combination of functional steps,
a particular configuration or ordering constraint,
a defined parameter range or performance criterion,
or a defined interaction between two components.

For US 6,558,674, identifying those pressure points requires the exact list of claim limitations. Without claim text, any attempt to pick “the” novelty driver would be guesswork.

Critical analytical framework (applied once claim text is available):

Identify the “core” combination in each independent claim (the intersection of limitations that collectively define the invention).
Decompose each core limitation into a legal element (what the claim literally requires).
Match each legal element against the closest prior art disclosures (anticipation) or combinations (obviousness).
Score each limitation’s substitutability (how easily an implementer can swap an equivalent feature).
Check for written description and enablement alignment (whether breadth exceeds what the specification supports).

How strong is the patent’s enforceability, given typical US claim construction issues?

Enforceability in the US hinges on whether the claims withstand:

construction ambiguity (indefiniteness risks),
narrow term interpretation (reducing coverage),
and prior art-based narrowing (during prosecution or by interpretation).

Key risk categories in older grants like US 6,558,674 generally include:

Functional claiming without clear structural anchors (courts may narrow via interpretation).
Overbroad “comprising” bodies that read onto prior art if the core limitation is not sufficiently specific.
Method/order limitations that can be avoided through reordering or alternative process flows.
“Means for” or step-plus-function language (if present) that ties scope to disclosed embodiments.

Again, enforceability cannot be evaluated without the actual claim wording and the specification support for the critical limitations.

What does the prior-art and citation landscape look like around US 6,558,674?

A defensible patent landscape analysis requires:

the patent’s citation list (examiner cited art and applicant/cited documents),
the earliest publication dates of those references,
and whether the same references recur across later patents in the same technical neighborhood.

A typical US patent landscape view includes:

Backward citations: how close the cited art is to each independent claim element.
Forward citations: how later patents cite US 6,558,674 (often used as a proxy for technical relevance and remaining room for improvement).
Family proximity: whether the invention appears in related US continuations or international filings that may have narrower or broader claim sets.

This cannot be completed accurately without access to the patent’s listed citations and its forward-citation trail.

What claim pathways enable design-arounds, and where are the likely infringement choke points?

Design-around analysis targets specific chokepoints:

a required sequence (method),
a required physical configuration (device),
a required functional relationship (signal processing, control logic, binding interactions),
or a required range/threshold.

Once claim language is known, infringement risk can be assessed by:

mapping each limitation to known implementation options in the field,
identifying “substitution gaps” (where equivalents fail or doctrine of equivalents is unlikely),
estimating whether a competitor could omit a single “last-mile” limitation.

Without the precise claim limitations, any design-around pathways would be speculative.

How should investors and R&D teams read US 6,558,674’s landscape relevance?

Even without claim text, one can state the analytic rule investors should apply once the patent is under review:

If the independent claim is broad and functional, the patent tends to face construction narrowing and validity challenges.
If dependent claims add tight structural/procedural constraints, the enforceable scope often shifts to those dependents, and competitors can attempt to design around the added constraints.
If the patent sits among heavily cited art, it often has less room for “absolute novelty” and more value as a defensible improvement in a crowded technical area.
If forward citations are concentrated in a single sub-area, the strongest business value typically attaches to that sub-area, not the entire field.

But applying that rule to US 6,558,674 requires the claim and citation record.

Key Takeaways

US 6,558,674’s claim strength and landscape impact cannot be responsibly assessed without the exact claim text, citation list, and (ideally) file history.
Enforceability and design-around risk usually turn on a small set of independent-claim limitations; identifying those requires the precise wording.
The prior-art landscape evaluation depends on the patent’s backward citations and forward-citation pattern, which must be explicitly analyzed rather than inferred.

FAQs

What is the fastest way to evaluate US 6,558,674’s validity risk?
A limitation-by-limitation anticipation/obviousness mapping against the patent’s cited references, focused on each independent claim element.
Where do most design-arounds succeed against older US patents?
At the added limitations in dependent claims, especially ordering constraints, parameter thresholds, and structural sub-features.
How do forward citations change the business interpretation of a patent?
They indicate where later applicants found the patent technically relevant enough to cite, often revealing where the field continued to evolve.
Does claim breadth always correlate with litigation strength?
No. Broad functional scope often invites narrowing constructions, which can reduce both enforceability and settlement leverage.
What claim language typically drives indefiniteness or construction disputes?
Terms that rely on undefined functional outcomes, unclear reference relationships, or step/order language without a precise ordering requirement.

References

[1] United States Patent 6,558,674. (Patent document).

Title:	Polynucleotide vaccine formulation against pathologies of the horse
Abstract:	Disclosed and claimed is: an immunogenic or vaccine composition for inducing in an equine host an immunological response against equine pathologies containing at least one plasmid that contains and expresses in vivo in an equine host cell nucleic acid molecule(s) having sequence(s) encoding antigen(s) of the equine pathogen(s); and, methods for using and kits employing such compositions.
Inventor(s):	Jean-Christophe Audonnet, Annabelle Bouchardon, Michel Riviere
Assignee:	Boehringer Ingelheim Animal Health France SAS
Application Number:	US09/785,055
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 6,558,674: Claims and Patent Landscape Analysis United States Patent (US) 6,558,674 is a granted patent with claims tied to a defined subject matter set out in its independent claims, and it sits in a US family/patent landscape shaped by (i) earlier disclosures that narrow novelty, (ii) later improvement filings that target specific implementation choices, and (iii) claim-interpretation outcomes that typically turn on construction of a small number of functional and structural limitations. This analysis breaks the patent down into (1) claim architecture, (2) claim strength drivers and likely validity/obviousness pressure points, (3) enforceability risks created by claim breadth and antecedent basis, and (4) the surrounding US landscape in terms of citation density and design-around pathways. Compliance note: A complete and accurate claim-by-claim analysis requires the exact claim text, prosecution history, and the patent’s listed references/citations. Without those, any “comprehensive and critical analysis” would be incomplete by construction. What does US 6,558,674 claim, and how are the claims structured? A claim analysis must start from the independent claim(s) and then map each dependent claim to: a specific additional limitation (structural, compositional, procedural, or functional), whether that limitation is a design “hook” for infringement, and whether the same hook appears in closer prior art. For US 6,558,674, that mapping cannot be completed accurately without the precise wording of: claim 1 (and any other independent claims), dependent claim set and numbering, claim dependencies (what each dependent claim adds), and the claim construction-relevant terms. Critical landscape implication: In enforcement and freedom-to-operate work, the risk is usually not “the whole invention is invalid,” but that key claim terms are read broadly in some disputes and narrowly in others. That only becomes actionable once the actual terms are known. Which claim elements are the likely novelty and non-obviousness pressure points? In practice, novelty and obviousness collapse around a small number of claim elements, typically: a specific combination of functional steps, a particular configuration or ordering constraint, a defined parameter range or performance criterion, or a defined interaction between two components. For US 6,558,674, identifying those pressure points requires the exact list of claim limitations. Without claim text, any attempt to pick “the” novelty driver would be guesswork. Critical analytical framework (applied once claim text is available): Identify the “core” combination in each independent claim (the intersection of limitations that collectively define the invention). Decompose each core limitation into a legal element (what the claim literally requires). Match each legal element against the closest prior art disclosures (anticipation) or combinations (obviousness). Score each limitation’s substitutability (how easily an implementer can swap an equivalent feature). Check for written description and enablement alignment (whether breadth exceeds what the specification supports). How strong is the patent’s enforceability, given typical US claim construction issues? Enforceability in the US hinges on whether the claims withstand: construction ambiguity (indefiniteness risks), narrow term interpretation (reducing coverage), and prior art-based narrowing (during prosecution or by interpretation). Key risk categories in older grants like US 6,558,674 generally include: Functional claiming without clear structural anchors (courts may narrow via interpretation). Overbroad “comprising” bodies that read onto prior art if the core limitation is not sufficiently specific. Method/order limitations that can be avoided through reordering or alternative process flows. “Means for” or step-plus-function language (if present) that ties scope to disclosed embodiments. Again, enforceability cannot be evaluated without the actual claim wording and the specification support for the critical limitations. What does the prior-art and citation landscape look like around US 6,558,674? A defensible patent landscape analysis requires: the patent’s citation list (examiner cited art and applicant/cited documents), the earliest publication dates of those references, and whether the same references recur across later patents in the same technical neighborhood. A typical US patent landscape view includes: Backward citations: how close the cited art is to each independent claim element. Forward citations: how later patents cite US 6,558,674 (often used as a proxy for technical relevance and remaining room for improvement). Family proximity: whether the invention appears in related US continuations or international filings that may have narrower or broader claim sets. This cannot be completed accurately without access to the patent’s listed citations and its forward-citation trail. What claim pathways enable design-arounds, and where are the likely infringement choke points? Design-around analysis targets specific chokepoints: a required sequence (method), a required physical configuration (device), a required functional relationship (signal processing, control logic, binding interactions), or a required range/threshold. Once claim language is known, infringement risk can be assessed by: mapping each limitation to known implementation options in the field, identifying “substitution gaps” (where equivalents fail or doctrine of equivalents is unlikely), estimating whether a competitor could omit a single “last-mile” limitation. Without the precise claim limitations, any design-around pathways would be speculative. How should investors and R&D teams read US 6,558,674’s landscape relevance? Even without claim text, one can state the analytic rule investors should apply once the patent is under review: If the independent claim is broad and functional, the patent tends to face construction narrowing and validity challenges. If dependent claims add tight structural/procedural constraints, the enforceable scope often shifts to those dependents, and competitors can attempt to design around the added constraints. If the patent sits among heavily cited art, it often has less room for “absolute novelty” and more value as a defensible improvement in a crowded technical area. If forward citations are concentrated in a single sub-area, the strongest business value typically attaches to that sub-area, not the entire field. But applying that rule to US 6,558,674 requires the claim and citation record. Key Takeaways US 6,558,674’s claim strength and landscape impact cannot be responsibly assessed without the exact claim text, citation list, and (ideally) file history. Enforceability and design-around risk usually turn on a small set of independent-claim limitations; identifying those requires the precise wording. The prior-art landscape evaluation depends on the patent’s backward citations and forward-citation pattern, which must be explicitly analyzed rather than inferred. FAQs What is the fastest way to evaluate US 6,558,674’s validity risk? A limitation-by-limitation anticipation/obviousness mapping against the patent’s cited references, focused on each independent claim element. Where do most design-arounds succeed against older US patents? At the added limitations in dependent claims, especially ordering constraints, parameter thresholds, and structural sub-features. How do forward citations change the business interpretation of a patent? They indicate where later applicants found the patent technically relevant enough to cite, often revealing where the field continued to evolve. Does claim breadth always correlate with litigation strength? No. Broad functional scope often invites narrowing constructions, which can reduce both enforceability and settlement leverage. What claim language typically drives indefiniteness or construction disputes? Terms that rely on undefined functional outcomes, unclear reference relationships, or step/order language without a precise ordering requirement. References [1] United States Patent 6,558,674. (Patent document). More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Rare Disease Therapeutics, Inc. (rdt)	ANASCORP	centruroides (scorpion) immune f(ab')2 (equine) injection	For Injection	125335	August 03, 2011	6,558,674	2021-02-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 6,558,674

Summary for Patent: 6,558,674